Balazs Medgyasszay

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

Luis Paz‐Ares, David Vicente, Ali Tafreshi et al. · Journal of Thoracic Oncology · 2020 · 633 citations · Full text

Protocol-specified Final Analysis, Medicine, Pembrolizumab Plus Chemotherapy +9

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Michael Boyer, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu et al. · Journal of Clinical Oncology · 2021 · 246 citations · Full text

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study

Toby M. Maher, Susanne Stowasser, Yasuhiko Nishioka et al. · The Lancet Respiratory Medicine · 2019 · 96 citations · Full text

Fibrosis, Extracellular Matrix Turnover, Inflammatory Lung Disease +7

Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials

Renata Ferrarotto, Ian C. Anderson, Balazs Medgyasszay et al. · Cancer Medicine · 2021 · 48 citations · Full text

97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407

Andrew Robinson, David Vicente, Ali Tafreshi et al. · Journal of Thoracic Oncology · 2021 · 24 citations

First-line Pembrolizumab, Advanced Squamous Nsclc, Medicine +8